Drug Development.

Area of Science:

• Neuroscience
• Immunology
• Pharmacology

Background:

• Alzheimer's disease (AD) is a leading cause of dementia, characterized by amyloid-beta (Aβ) aggregation.
• Current therapies target Aβ, but there's a need for agents with high selectivity for aggregated Aβ species.
• Existing treatments face challenges, including potential vascular side effects and the need for more potent agents.

Purpose of the Study:

• To develop and characterize SNP234, a novel monoclonal antibody targeting soluble Aβ (sAβ) aggregates.
• To assess SNP234's selectivity, binding affinity, and efficacy in clearing Aβ aggregates compared to existing antibodies.
• To evaluate SNP234's potential as a next-generation immunotherapy for AD.

Main Methods:

• Developed SNP234, a monoclonal antibody with high selectivity for sAβ aggregates.
• Assessed binding affinities to various Aβ species using direct and competition assays.
• Evaluated SNP234's binding to human AD brain sections and its Aβ clearance activity.

Main Results:

• SNP234 demonstrated sub-nanomolar affinity for sAβ aggregates with minimal binding to monomer Aβ.
• The antibody showed robust binding to disease-associated amyloid plaques in human AD brain tissue.
• SNP234 proved efficacious in removing human amyloid plaques and exhibited favorable developability for subcutaneous formulation.

Conclusions:

• SNP234 exhibits high selectivity for toxic Aβ forms and effectively removes disease-associated Aβ.
• These findings support SNP234's further development as a potential best-in-class anti-amyloid immunotherapy.
• Subcutaneous administration of SNP234 represents a promising next-generation therapeutic strategy for AD.